Skip to content

Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation

Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01608477
Acronym
BRIGHT
Enrollment
1365
Registered
2012-05-31
Start date
2012-03-31
Completion date
2020-12-31
Last updated
2019-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Transplantation

Keywords

Heart transplantation, Medication adherence, Behavior system factor

Brief summary

Over the past decades, survival rates in heart transplantation recipients improved significantly, due to advancements in regimens of immunosuppressives and surgical techniques, but are still limited to the first 12 months post transplantation. Long-term survival remains almost unchanged indicating the need to identify and improve relevant factors. Evidence in other chronically-ill patient populations shows that the healthcare system (e.g. level of chronic illness management (CIM)) and patient self-management (e.g. adherence) drive improvements in outcomes. The BRIGHT study is the first multi-centre, multi-continental study examining healthcare system and heart transplant centres chronic illness management practice patterns and potential correlates of immunosuppressive medication nonadherence. The knowledge gained will inform clinicians, researchers and healthcare policy makers about the level(s) interventions need to be implemented at to improve long-term outcomes for transplant recipients.

Detailed description

Background: After receiving a heart transplant (HTx) patients have to adhere to a number of health behaviors (e.g., medication taking, and smoking cessation) in order to guarantee optimal outcomes. Non-adherence to these health behaviors is associated with poor clinical and economic outcomes. However, the prevalence of non-adherence to these health behaviors is high among HTx recipients. Furthermore, differences in prevalences among countries and continents are observed. The extent to which a HTx recipient is adherent is affected by a variety of risk factors, namely 1) patient-related factors, 2) socioeconomic factors, 3) therapy-related factors, 4) health-related factors and 5) healthcare system and team factors. To-date, this last group of factors only received limited attention in understanding the complex phenomena of adherence. Aims: The aims of this study are: 1. To describe CIM practice patterns among centres, countries/continents in HTx. 2. To assess the prevalence and variability of nonadherence to treatment regimen, i.e. medication taking, smoking cessation, diet keeping, alcohol consumption, physical activity, sun protection and appointment keeping in HTx recipients among centres, countries/continents. 3. To determine which multi-level factors are related to immunosuppressive medication adherence at the different system levels 4. To benchmark the participating centres, countries and continents in relation to CIM practice patterns and non-adherence to health behaviours Methodology: The BRIGHT study is an international, multi-center, cross-sectional study. Data were collected using interviews and questionnaires. HTx recipients, nurses working in the post-transplantation care of HTx recipients and the medical directors of the HTx programs were surveyed. The investigators recruited a convenience sample of 36 heart transplantation centers (North America (n= 12), European (n= 19), Australia (n= 2) and South America (n= 3)). Within participating centers, a random sample of patients who met the study eligibility criteria was selected. Per center, a minimum of 20 and a maximum of 60 patients were included. In total, 1677 heart transplant recipients were invited to participate in this study. The questionnaires used in this study will be existing questionnaires (e.g. BAASIS interview to assess adherence with medications, DASS to assess depression) as well as questionnaires developed for this study. During a regular follow-up visit, patients were invited by a staff person to participate in this study. The staff first informed the patient about the study and, if the patient was willing to participate, retrieved a signed informed consent. Participating in this study was voluntary. Informed consent of the nurses and the medical director of the transplant center were implied by completing the questionnaires. Participant names will be held in strict confidence and will remain anonymous in research reports or publications. The results of the benchmarking of the parameters assessed in this study will be reported by figures and tables. Because of privacy, the HTx centers can only identify the parameters specific to their center. All other information will be reported anonymously.

Interventions

None listed

Sponsors

KU Leuven
CollaboratorOTHER
University of Missouri, Kansas City
CollaboratorOTHER
Universitaire Ziekenhuizen KU Leuven
CollaboratorOTHER
Hospital Universitario À Coruña, Spain
CollaboratorUNKNOWN
Azienda Ospedaliero, Universitaria Pisana
CollaboratorOTHER
Hannover Medical School
CollaboratorOTHER
Johns Hopkins University
CollaboratorOTHER
US Department of Veterans Affairs
CollaboratorFED
George Washington University
CollaboratorOTHER
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
CollaboratorOTHER
Hopital Louis Pradel
CollaboratorOTHER
Hôpital Nord Laennec, France
CollaboratorUNKNOWN
Groupe Hospitalier Pitie-Salpetriere
CollaboratorOTHER
University Hospital Heidelberg
CollaboratorOTHER
University Hospital, Udine, Italy
CollaboratorOTHER
University of Bologna
CollaboratorOTHER
Hospital de Sant Pau
CollaboratorOTHER
Puerta de Hierro University Hospital
CollaboratorOTHER
Hospital Universitario La Fe
CollaboratorOTHER
Hospital Universitario Reina Sofia de Cordoba
CollaboratorOTHER_GOV
Insel Gruppe AG, University Hospital Bern
CollaboratorOTHER
University Hospital, Zürich
CollaboratorOTHER
Papworth Hospital NHS Foundation Trust
CollaboratorOTHER_GOV
Freeman Hospital, UK
CollaboratorUNKNOWN
Royal Brompton & Harefield NHS Foundation Trust
CollaboratorOTHER
Toronto General Hospital
CollaboratorOTHER
University of Ottawa Heart Institute, Canada
CollaboratorUNKNOWN
St. Paul's Hospital, Canada
CollaboratorOTHER
London Health Sciences Centre
CollaboratorOTHER
Duke University Hospital, USA
CollaboratorUNKNOWN
Virginia Commonwealth University
CollaboratorOTHER
The Cleveland Clinic
CollaboratorOTHER
Cedars-Sinai Medical Center
CollaboratorOTHER
Kaiser Permanente
CollaboratorOTHER
St Luke's Hospital, USA
CollaboratorUNKNOWN
Hospital of the University of Pennsylvania, USA
CollaboratorUNKNOWN
Ochsner Health System
CollaboratorOTHER
Hospital Israelita Albert Einstein
CollaboratorOTHER
Instituto Dante Pazzanese de Cardiologia
CollaboratorOTHER
Instituto do Coração da Universidade de São Paulo, Brazil
CollaboratorUNKNOWN
St Vincent's Hospital, Sydney
CollaboratorOTHER
The Prince Charles Hospital
CollaboratorOTHER_GOV
Astellas Pharma Europe Ltd., UK
CollaboratorUNKNOWN
University of Basel
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Heart transplant patients * 18 years or older at time of inclusion * Transplanted and followed-up for routine care in a participating transplant center * First transplant * Single-organ transplant * Between 1 and 5 years post-transplant * Ability to read, understand and sign written informed consent (in Dutch, English, French, German, Spanish, Italian, or Portuguese, depending on the languages spoken within the country where the participating transplant center is located) * Provided written informed consent

Exclusion criteria

* Receiving professional support in medication taking * Involved in adherence-intervention research or drug trials during the past 6 months

Design outcomes

Primary

MeasureTime frameDescription
Self-reported non-adherence to immunosuppressive medicationOnceParticipants will be asked about immunosuppressive medication taking during the prior 4 weeks

Secondary

MeasureTime frameDescription
Self-reported adherence to smoking cessationOnceParticipants will be asked about current and past smoking
Self-reported adherence to dietary modificationsonceParticipants will be asked about adherence to dietary recommendations during the past year
Self-reported alcohol useOnceParticipants are asked about alcohol intake during the past year
Self-reported non-adherence to other medications (excl. immunosuppressive medications)OnceParticipants will be asked about adherence to other medications (excl. immunosuppressive medications) during the prior 4 weeks
Self-reported adherence to sun protectionOnceParticipants will be asked about the routine use of sun protection measures
Self-reported adherence to appointment keepingOnceParticipants will be asked if they kept the last five appointments with the transplant team
Self-reported adherence to physical activityOnceParticipants are asked about their level of physical activity during the past week

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026